2013
Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients
Kirst M, Li E, Wang C, Dong H, Liu C, Fried M, Nelson D, Wang G. Deep Sequencing Analysis of HCV NS3 Resistance-Associated Variants and Mutation Linkage in Liver Transplant Recipients. PLOS ONE 2013, 8: e69698. PMID: 23922778, PMCID: PMC3726766, DOI: 10.1371/journal.pone.0069698.Peer-Reviewed Original ResearchConceptsResistance-associated variantsProtease inhibitorsChronic HCV infectionLiver transplant recipientsHCV drug resistanceFuture therapeutic strategiesHCV protease inhibitorsMutation linkageHigh-level resistanceLow levelsPI monotherapyTransplant recipientsHCV infectionLiver transplantLiver transplantationAntiviral therapyHCV populationTherapeutic strategiesViral variantsDrug resistanceDecreased susceptibilityQuasispecies populationPatientsDominant variantDeep sequencing analysis
2012
Histopathologic Resolution of Adult Liver Transplantation Adenovirus Hepatitis With Cidofovir and Intravenous Immunoglobulin: A Case Report
Kerensky T, Hasan A, Schain D, Trikha G, Liu C, Rand K, Soldevila-Pico C, Gupte A. Histopathologic Resolution of Adult Liver Transplantation Adenovirus Hepatitis With Cidofovir and Intravenous Immunoglobulin: A Case Report. Transplantation Proceedings 2012, 45: 293-296. PMID: 23267812, DOI: 10.1016/j.transproceed.2012.06.059.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsTransplant recipientsHistopathologic resolutionFatal outcomeAdult solid organ transplant recipientsAdult liver transplant recipientsAdult renal transplant recipientsClearance of viremiaCombination of cidofovirPatient's fatal outcomeLiver transplant recipientsRenal transplant recipientsLiver biopsy specimenSpecific treatment modalitiesPositive immunohistochemical stainingAdV diseaseIntravenous cidofovirIntravenous immunoglobulinAdenovirus hepatitisCombination therapyBiopsy specimenCase reportTreatment modalitiesPolymerase chain reactionInterleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease
Hanash A, Dudakov J, Hua G, O’Connor M, Young L, Singer N, West M, Jenq R, Holland A, Kappel L, Ghosh A, Tsai J, Rao U, Yim N, Smith O, Velardi E, Hawryluk E, Murphy G, Liu C, Fouser L, Kolesnick R, Blazar B, van den Brink M. Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease. Immunity 2012, 37: 339-350. PMID: 22921121, PMCID: PMC3477611, DOI: 10.1016/j.immuni.2012.05.028.Peer-Reviewed Original ResearchConceptsIL-23-responsive innate lymphoid cellsIntestinal IL-22IL-22Intestinal stem cellsTissue damageHost diseaseTransplant recipientsIL-22 deficiencyInflammatory intestinal damageDonor immune systemInnate lymphoid cellsBone marrow transplantIL-22 receptorStem cellsILC frequenciesPretransplant conditioningIntestinal damageMarrow transplantCrypt apoptosisLymphoid cellsImmune systemGVHDTissue sensitivityProtective factorsEpithelial integrity
2005
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplantSustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
2002
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
Reddy P, Teshima T, Hildebrandt G, Williams D, Liu C, Cooke K, Ferrara J. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2002, 101: 2877-2885. PMID: 12433681, DOI: 10.1182/blood-2002-08-2566.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsBone Marrow TransplantationFemaleGraft vs Host DiseaseGraft vs Leukemia EffectHumansInterferon-gammaInterleukin-18Leukemia, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLSTAT6 Transcription FactorSurvival RateTissue DonorsT-LymphocytesTrans-ActivatorsTransplantation, HomologousConceptsAllogeneic bone marrow transplantationBone marrow transplantationPretreatment of donorsIL-18Acute GVHDAcute graftHost diseaseLeukemia effectTransplant donorsCytotoxic T lymphocyte activityAcute GVHD mortalityIL-18 pretreatmentDonor T cellsT lymphocyte activityBM transplant recipientsIL-4 secretionSTAT6-dependent mechanismIL-18 treatmentGVHD mortalityGVL effectPreserves graftTransplant recipientsInterleukin-18Marrow transplantationBM donors